07 September 2018
A new report by visiongain, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.
Visiongain is a business information publisher and consultancy based in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.
“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”
First visiongain’s new study provides revenue forecasts to 2026 for five submarkets and the overarching world market:
• Antibody-drug conjugates
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and ALPs
• Biosimilar antibodies.
In addition that investigation shows revenue forecasts to 2026 for seven drugs:
That analysis also shows revenue forecasts to 2026 for four regional markets:
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the world.
The new report discusses forces stimulating sales growth over the next ten years, as well as forces restraining that industry and market. That work also shows interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics.
Next-Generation Antibody Therapies Market Forecast 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.